Status:
RECRUITING
Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Li An
Conditions:
Chronic Obstructive Pulmonary Disease Severe
Eligibility:
All Genders
40-85 years
Brief Summary
This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for p...
Eligibility Criteria
Inclusion
- Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC\<70%, FEV1% predicted value ≤ 50% after Bronchiectasis)
- Age\>40 years old
- COPD stable for more than 4 weeks
- Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month
- Patient informed and signed consent form
Exclusion
- Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis
- Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease)
- History of chronic diarrhea or constipation
- History of Gastrointestinal Surgery
- Using probiotics or antibiotics within the past 4 weeks
- No history of using oral hormones or traditional Chinese medicine in the past three months
- Pregnancy or lactation
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
365 Patients enrolled
Trial Details
Trial ID
NCT06198309
Start Date
May 1 2023
End Date
December 1 2027
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chaoyang Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China, 100000